Spectrin Breakdown Products (SBDPs) as Potential Biomarkers for Neurodegenerative Diseases

Abstract

The world’s human population ages rapidly thanks to the great advance in modern medicine. While more and more body system diseases become treatable and curable, age-related neurodegenerative diseases remain poorly understood mechanistically, and are desperately in need of preventive and therapeutic interventions. Biomarker development consists of a key part of concerted effort in combating neurodegenerative diseases. In many chronic neurodegenerative conditions, neuronal damage/death occurs long before the onset of disease symptoms, and abnormal proteolysis may either play an active role or be a companying event of neuronal injury. Increased spectrin cleavage yielding elevated spectrin breakdown products (SBDPs) by calcium-sensitive proteases such as calpain and caspases has been established in conditions associated with acute neuronal damage such as traumatic brain injury (TBI). Here we review literature regarding spectrin expression and metabolism in the brain, and propose a potential use of SBDPs as biomarkers for neurodegenerative diseases such as Alzheimer’s diseases.

Introduction

The spectrin family proteins are enriched membrane-associated molecules initially discovered in human red blood cells and then identified ubiquitously in various types of cells of bodily tissues including the brain [1-4]. The most recent exciting discoveries in spectrin research includes the identification of essential biological functions of these proteins in the brain during neurodevelopment and synaptoplasticity, association of these proteins with particular neuronal structural domains, and findings of genetic link of these proteins to certain inherited neurological diseases such as spinocerebellar ataxia [3-7]. Potentially with a broader relevance in disease neurobiology, spectrin metabolism is intrinsically linked to membrane/cytoskeleton maintenance, dynamics, remodeling and degradation, but also involves processes of protein cleavage, recycling and clearance [6, 7]. In the event of neuronal stress, injury and death under acute and chronic degenerative conditions, enhanced catabolism of membrane/cytoskeleton proteins occurs, leading to elevation of their breakdown products. Such a process provides a plausible rationale for seeking potential biomarkers for neurodegenerative disorders. Increased calpain and caspase-3 mediated spectrin breakdown products (SBDPs) are found in a number of acute and subacute neurodegenerative conditions including traumatic brain injury (TBI) [8-10]. Cerebrospinal fluid (CSF) and blood SBDPs are being evaluated as novel biomarkers for TBI in the clinic [11]. Ample evidence also exists suggestive of calpain/caspase-3 activation and enhanced spectrin proteolysis during brain aging, and in Alzheimer’s disease (AD) and other age-related neurodegenerative disorders [12, 13].

In this review, we will first briefly introduce some general aspects of spectrin biology and the expression of brain spectrin. We then discuss spectrin proteolysis especially by the calcium-dependent calpain and caspase-3 proteases as characterized in cell biology studies, and the development of SBDPs as novel biomarkers for TBI and cerebral ischemia. We will further review literature regarding calpain and caspase-3 activation and spectrin alterations during aging and in chronic neurodegenerative diseases, especially AD. Finally, we present preliminary observation of SBDP120 accumulation in transgenic AD model, and propose an application of SBDPs as potential biomarkers in age-related neurodegenerative diseases such as AD.

Overview of spectrin biology

Much of spectrin basic cell biology, subcellular localization, molecular interaction, functions and disease relevance are learned from studies of the protein in red blood cells, which has been intensely discussed in many timely reviews [2-4, 14-18]. Overall, erythroid spectrin is composed of two monomeric components, namely α and β subunits, which connect each other laterally to form a dimmer that are further paired head-to-head to produce tetramers. The tetramers are then associated end-to-end with the short actin filaments to produce a basic hexagonal network located on the inner surface of red blood cell membrane. The β-spectrin subunits also contain binding sites for several other proteins, including ankyrin, protein 4.1, tropomyosin, tropomudulin, adducin and glycophorin C [19-26]. The resulting spectrin meshwork complex appears to play an essential role in red blood cells to afford their morphological stability and flexibility and functions, including maintaining a biconcave morphology and changing shape in the circulation [17, 18]. The importance of erythroid spectrin complex in hematology has been implicated by the fact that genetic mutations of α-spectrin, β-spectrin, ankyrin or protein 4.1 cause several forms of hereditary hemolytic anemia [4, 17, 18]. The spectrin membrane network is also expected to play a much broader biological role by providing orderly anchoring, trafficking and dynamics of integral proteins within the lipid bilayer [3, 26, 29, 30].

A fundamental biological role of the spectrin family proteins is implicated by a conservative presence of the protein in bodily cells and during organism evolution. The spectrin gene family has expanded from invertebrates to vertebrates including mammals, with one α and two β genes coding spectrin subunits in invertebrates, whereas two α spectrins (αI and αII) and five β spectrins (βI to V) coding the spectrin proteins in vertebrates including humans [4]. In humans, the SPTA1 gene encodes the αI-spectrin expressed in erythrocytes; its mutations result in hereditary disorders including elliptocytosis type 2, pyropoikilocytosis, and spherocytic hemolytic anemia [4, 15-17]. The SPTAN1 gene encodes αII-spectrin expressed specifically in nonerythrocytic cells including neurons, with its mutations associated with early infantile epileptic encephalopathy-5 [27]. The SPTB gene codes the erythroid β spectrin subunit in humans [28], which is related to some form of hereditary spherocytosis as well [29]. The SPTBN1, SPTBN2, SPTBN4 and SPTBN5 genes appear to largely code the non-erythroid β-spectrin variants, named in order as βI, βIII, βIV and βV-spectrins, which are expressed in various tissues of the body [4, 16]. Mutations of some of the non-erythroid β-spectrin subunits could be associated with certain inherited diseases [30-34].

Spectrin expression in the nervous system

One of the most important extensions from the early erythroid spectrin research has been in the field of neuroscience, and brain spectrin perhaps represents the best-studied non-erythroid member of this protein family. In general, the brain appears to be considerably rich of spectrin, which is estimated to comprise about 3% of the total membrane protein [35, 36]. The major brain spectrin variants are the ∀II subunit and the βII, βIII and βIV subunits, while it remains unclear if there is a differential expression of these subunits among neuronal/glial subpopulations [36, 37]. In immunoelectron microscopy, spectrin immunoreactive products are concentrated in neuronal cell bodies, dendrites, and postsynaptic terminals, with labeling prominently associated with the plasma membrane, microtubules, filaments, mitochondria, endoplasmic reticulum, and nuclear envelope [31, 38]. As expected, spectrin expression has been also identified in glial cells in the central and peripheral nervous systems, including oligodendrocytes, astrocytes and Schwann cells [39]. As with their erythroid counterparts, brain spectrin subunits cross-link with actin filament and other proteins such as ankyrin, consisting with a major and general function of the protein in membrane skeleton formation, maintenance and plasticity [4, 26, 36]. Importantly, brain spectrin appears to be “specialized” at certain neuronal compartments to serve unique neurobiological roles that involve special assembly of local membrane domain and/or dynamic membrane/cytoskeletal modulation. For instance, brain spectrin proteins participate in assembly of specialized membrane proteins at the initial axonal segment, Ranvier’s node, growth cone, and pre- and postsynaptic components [40-48]. Thus, neuronal and glial spectrin may play fundamental roles during membrane/cytoskeletal remodeling and rearrangement events, e.g., neuronal development and migration, neuritic polarization and outgrowth, and synaptogenesis and plasticity [40-53].

At least one hereditary neurological disorder, called spinocerebellar ataxia type 5 (SCA5), is associated with spectrin mutations with the βIII-spectrin gene (SPTBN2). This was first identified in a family descended from the grandparents of President Lincoln [54], and later in three other families [5, 54]. The disease is pathologically characterized by Purkinje cell degeneration. Subsequent experimental genetic studies in drosophila show that the mutant βIII-spectrin disrupts fundamental intracellular protein transportation [54]. In a mouse model lacking full-length βIII spectrin, animals recapitulate many clinical and pathological features of SCA5, including gait abnormalities, tremor, deteriorating motor coordination and cerebellar atrophy [55]. Disruption of dendritic arborization and spine formation in Purkinje cells occurs in βIII-spectrin knockout mice during development. These defects appear to affect largely dendritic but not axonal development, suggesting a critical role of the spectrin protein in neuronal development [50, 52-55].

Spectrin proteolysis in neuronal injury and death

Spectrin catabolism would involve multiple events such as proteolysis, ubiquitination, intracellular trafficking/sequestration, and release/exocytosis of breakdown products [56, 57]. The proteolytic process has been mostly studied so far, largely under acute or subacute stressful conditions in vitro and in vivo. Both αII and βII spectrin proteins may undergo enzymatic cleavages by calpain and caspase-3 [58-62]. αII-Spectrin (280 kDa) is a major substrate for calpain and caspase-3 proteases, and can produces multiple breakdown products with distinct molecular sizes. Calpain mediated degradation of αII-spectrin results in the formation of two unique and highly stable SBDPs migrated at 150 kDa and 145 kDa (SBDP150 and SBDP145), which can be further cleaved by caspase-3 yielding shorter fragments including SBDP120. The presence of the calpain-cleaved fragments occurs early in neural cell pathology and may be indicative of necrotic and excitotoxic neuronal injury and death. Caspase-3 mediated αII-spectrin degradation yields the formation of 150 kDa SBDP, which is further cleaved into a 120 kDa fragment (SBDP120) and appears to be indicative of apoptotic death. A number of antibodies are thus developed to detect different spectrin breakdown products, which may help determine cell death mediated by calpain and/or caspase cleavages and assess neuronal injury and death in vivo including in clinical setting [8-11, 58-62].

The causal relationship between intracellular calcium rise, calpain activation and spectrin breakdown has been well-established in vivo and ex vivo (organotypic culture) in the hippocampal formation [63]. Thus, pharmacological stimulation of NMDA receptors activates calpain-dependent spectrin proteolysis leading to elevations of SBDPs and signs of neuronal degeneration that both can be blocked by NMDA antagonists [64-66]. Similarly, calpain activation associated with increased neuronal SBDP immunoreactivity and cell loss occurs in the hippocampus and piriform cortex following kainate-induced excitotoxicity and seizure [66, 67]. Enhanced spectrin breakdown and/or elevation of SBDPs also occur in the other parts of the central nervous system as a result of hypoxia and ischemia. In ex vivo retinal preparations, hypoxia upregulates calpain and its mediated αII-spectrin proteolysis leading to increased levels of SBDP150 [68]. Both calpain and caspase-3 specific SBDPs are elevated in the retina following intraocular hypertension, an experimental glaucoma [69]. In a typical gerbil model of global ischemia, transient (5 minute) carotid artery occlusion results in elevation of SBDP150 in the forebrain for up to 15 days [70].

The use of CSF SBDPs as biomarkers for neuronal injury is currently explored experimentally and clinically for a number of neurological conditions. Elevation of calpain and caspase specific SBDPs in CSF following TBI has been established in multiple human subject studies, and appears to be correlated with the severity of injury, computed tomography scan findings, and clinical outcomes [8, 11, 71, 72]. The temporal profiles of CSF SBDPs change appear of predictive value for clinical outcome, with persistent SBDP elevation associated with worse recovery. Levels of SBDP150 and SBDP145 are predominantly elevated during the early phase post-TBI, while SBDP120 levels remain elevated for a longer post-injury period. This pattern suggests that both necrotic/oncotic and apoptotic cell death mechanisms are activated after TBI, but may proceed with different time courses after injury [8, 71, 72]. Besides TBI, accumulation of calpain-cleaved αII-SBDPs are detectable in the CSF in rats subjected to 2 hours of transient focal cerebral ischemia by middle cerebral artery occlusion followed by reperfusion [61], and in a canine model of hypothermic circulatory arrest [9]. These findings point to a potential utility of CSF SBDPS as biomarkers for ischemic brain damages in addition to TBI in humans. One may expect that neuronal spectrin degradation by calcium-dependent proteases calpain and caspase-3 may occur under diverse conditions and potentially reflect an early but general event in neural cell pathology [7].

Neuronal injury/death signaling in chronic neurodegenerative diseases

While the underlying etiological cause, brain regional vulnerability, cellular neuropathology and clinical manifestation are significantly different, many age-related neurodegenerative diseases including AD, Parkinson’s disease (PD) and Huntington’s disease (HD) appear to be associated with chronic neuronal stress, injury and death, which are believed to begin and progress over a long period of time before the appearance of presenting clinical symptoms in each disease [73-76]. Neuronal degeneration in these chronic disease paradigms appears to exhibit many molecular and cellular characteristics similar to that seen during the course of acute neuronal injury and death following traumatic, ischemic or other stressful insults. As well-recognized in the field, calcium dyshomeostasis and calcium-induced activation of proteases, including calpain and caspases, may contribute to neuronal death in a wide variety of neurodegenerative diseases [74-76]. For example, increased calpain II (m-calpain) is found in vulnerable brain regions in PD [77]. Activation of the calpain/cdk5/p25 pathway is evident in the cingulate gyrus in PD [78]. In fact, calpain participates in alpha-synuclein cleavage and play a role in alpha-synuclein aggregation and pathogenesis [79]. Similarly, activated calpain has been detected in the caudate of human HD tissue but not in age-matched controls [80]. In fact, both calpain and caspse-3 are key proteases for huntingtin degradation [79, 80]. In AD, widespread calpain activation and the upregulation of the caspase signaling pathway appear to occur early and persistent in brain [81-84]. Again, the calcium-sensitive proteases are involved in the cleavages of some disease-signature proteins in AD, including β-amyloid precursor protein (APP) [85], β-secretase (BACE1) [86] and tau [87]. Thus, calcium deficits and associated cell injury/dearth signaling activation are likely early and fundamental events in various neurodegenerative diseases, pointing to novel molecular targets of disease intervention and as well as avenues for the development of diagnostic biomarkers.

Spectrin proteolysis and SBDPs in aging and Alzheimer’s disease

A fair amount of evidence suggests that calcium deregulation and increased proteolysis of spectrins may exist in the brain during normal aging and in AD [12, 84-87, 90-92]. In mouse and rat brains, levels of SBDPs elevate with age especially in the forebrain, largely involving the calpain specific species SBDP150 and SBDP145 [93, 94]. Altered spectrin and SBDP150 immunoreactivity is reported in AD human brain [13], with abnormal spectrin labeling occurred in neuronal processes and axon terminals, which may represent atypical axonal and dendritic elements from sprouting neurons or accumulation of SBDPs in degenerating neurons. In another human brain study, accumulation of SBDP120 is found in AD but not age-matched control brains, predominantly localizing to a subpopulation of layers III and V cortical pyramidal neurons [95]. These findings are in congruence with existing anatomic and biochemical evidence indicating calpain overexpression and activation in this disease [84-87]. Potentially relevant to aging or AD cell biology, enhanced spectrin proteolysis and elevation of SBDPs can be detected in cultured skin fibroblasts from aged and AD donors as compared to young adult controls [12], and in red blood cells and lens during aging [91, 92].

Two recent studies have shown alteration of SBDPs in the CSF and/or brain in AD subjects and transgenic mouse models of AD relative to controls. Higuchi et al analyzed CSF samples from 14 living AD patients and 9 age-matched normal controls [86], showing that CSF levels of the 150 and 145 kDa SBDPs elevated over 2.5 fold in AD relative to control cases, with the ratio of cleaved to full-length species increased more than 3 fold in the former group. In 16 month-old mice expressing mutant human APP, levels of a calpain cleaved α-spectrin (136 kDa) increased about 10 fold in the hippocampal extracts relative to non-transgenic control. In immunohistochemistry, putative SBDP150 labeling was identified in dystrophic neurites surrounding amyloid plaques [86]. In another study, SBDP150 levels were found increased by western blot in the hippocampus in APP/presenilin-1 double-transgenic mice relative to non-transgenic controls [96]. Interestingly, blocking calpain activity by genetic overexpression of an endogenous calpain inhibitor, calpastatin, caused a remarkable decrease of amyloid plaque pathology by immunohistochemistry and also prevented Tau phosphorylation in biochemical analysis [96].

Using a set of new antibodies, we are currently examining potential SBDP accumulation in the brain during normal aging, and in transgenic models of AD relative to control by anatomical and biochemical approaches. Preliminary western blot data indicated elevations of SBDP150 and SBDP145 in aged rat and mouse brains, more robust in AD transgenic animals, consistent with a notion of calpain overexpression/activation facilitating spectrin cleavages. Interestingly, a rabbit antibody targeting the caspase-3 cleavage site in αII-spectrin detected SBDP120 by western blot, but displayed selective regional and cellular labeling in aged rat forebrain. In rats, SBDP120 protein levels elevated in the cerebral cortex and olfactory bulb by 16 months relative to 4 and 8 months of age (Fig. 1A, B). This antibody also revealed age-dependent but region and cell-type specific labeling in 16 month-old rats, occurring largely in layer V pyramidale-like cortical neurons and some dendritic elements (Fig. 1C, D), and distinctly at the apical dendrites of the olfactory bulb mitral cells (Fig. 1G, J, arrows). SBDP120 protein levels and intraneuronal immunoreactivity were increased age-dependently in the cerebral cortex and olfactory bulb in the triple transgenic AD (3xTg-AD) model mice relative to non-transgenic (non-Tg) counterparts (unpublished observation). Interestingly, in the transgenic mice that harbor five familial AD (FAD) related mutations (5XFAD), which undergo an aggressive amyloid pathogenesis [97], robust astrocytic SBDP120 immunolabeling was detectable in many forebrain areas before mid-age, whereas little astrocytic reactivity was seen in non-transgenic controls. This finding is surprising, and remains to be clarified whether glial cells may contribute to SBDP formation in the brain or they may uptake and further process SBDPs derived from neurons. Regardless, it appears that transgenic AD models may be useful for analyzing spectrin proteolysis and SBDPs accumulation in the brain, which may be informative for future characterization of the pathology in AD.

Figure 1.

Preliminary characterization of an age-related accumulation of SBDP120 in rodent brain with a new rabbit polyclonal antibody. The antibody detects a band at 120 kDa in rat forebrain extracts by western blot (A), with its banding signal increased in the cortex and olfactory bulb at 16 relative to 4 and 8 months of age (A, B), as also seen in immunolabeling in the cortex (C, D). SBDP120 immunoreactivity is substantially increased in the olfactory bulb (OB), cerebral cortex (Ctx) and hippocampal formation in an 8 month-old 5XFAD mouse (E, F) relative to an age-matched non-transgenic (non-Tg) control (H, I). The labeling is strikingly expressed in astrocytic glia in the transgenics (G). However, neuronal labeling is readily evident in the olfactory nerve terminals (E, H, J) and around the mitral cell layer (MCL) (G, J, arrows). The latter labeling was identified to occur at the somotodendritic junction and apical dendrites of the mitral cells. Pir: piriform cortex; WM: white matter; DG: dentate gyrus; GL: glomerular layer; EPL: external plexiform layer. Scale bar = 300 μm for C, D, G, J, and 1 mm for E, F, H and J.

SBDPS as putative biomarkers for neurodegenerative diseases

As discussed in preceding sections, spectrin proteins are enriched constitutive cellular components that play vital biological roles in membrane/cytoskeleton stability, dynamics and remodelling. In the brain, such structural cellular modulations are constant and essential to support neuronal and synaptic plasticity, mediated at least in part by activity-dependent calcium signaling that activates effector proteases including calpain and caspases to execute site-specific and temporal degradation of specific proteins such as spectrin, allowing membrane/cytoskeleton reassembly to take place [6, 7]. Aberrant activation of calpain and caspases by calcium overflow is an early cellular response to many stressful and potentially pathogenic insults, which, if persistent, can lead to membrane/cytoskeleton destruction and death in vulnerable populations of cells. As established in traumatic and ischemic brain injuries, calcium triggered calpain and caspases-3 activation cause excessive spectrin proteolysis and subsequent elevation of SBDPs in the brain and CSF [8-10, 60-63]. Mounting evidence supports the existence of calcium dyshomeostasis and its consequent activation of calpain and caspases in aging cells/brain and age-related neurodegenerative diseases including AD, PD and HD. Early and emerging new data point to abnormality of spectrin degradation and accumulation of SBDPs in the brains from AD subjects and transgenic animal models [13, 86]. Accordingly, we propose that SBDPs may serve as novel biomarkers for chronic neurodegenerative diseases such as AD, and solicitate further exploration toward this direction.

Developing and validating specific antibodies for detection of SBDPs are the crucial first steps for such an effort. For instances, antibodies that selectively detect SBDPs but not the hiding epitope(s) in the uncleaved spectrin proteins would be of particular importance in characterization of SBDP accumulation in the brain and CSF in anatomical and biochemical assays. Antibodies that may specifically recognize brain or neuronal spectrin cleavage products would be of advantage by allowing analysis of the products in CSF and perhaps in blood. Antibodies that preferentially recognize calpain and caspase specific fragments may help understand the sequential or orderly processing of spectrin cleavages executed by these enzymes anatomically and biochemically in the brain and in model cell systems. Anatomically usable specific SBDP antibodies are essential for profiling the spatiotemporal course of physiological verse pathophysiological spectrin cleavage and accumulation of SBDPs relative to cellular integrity or pathogenic progression.

As discussed earlier, calcium-dependent calpain and caspase activation and resultant spectrin proteolysis and SBDP elevation appear to represent a general event in acute and chronic neurodegenerative conditions. Therefore, sensitivity and specificity are issues of concern in regard to the application of SBDPs as biomarkers for neurodegenerative diseases. Conceivably, a biomarker or diagnostic tool needs to be used adjunctively, in combination with other laboratory measurements, clinical history and symptom presentations. Obviously, basic and translational investigations are required to further determine whether SBDPs are useful for assessing a certain aspect of neuropathology in age-related neurodegenerative diseases. Currently, numerous animal models of these diseases are available for initial studies of SBDPs in the brain and CSF. For instance, anatomical and biochemical examination of SBDP accumulation in the brain of transgenic AD model rodents may reveal data about the extent, localization and time course of SBDP alterations relative to development of amyloid plaques, tauopathy and neuronal death. Such comparatively animal studies may provide information for further investigation into the role and position of aberrant proteolysis and SBDP accumulation in the human brain during aging and in AD.

Conclusions

As an abundant membrane protein, spectrin is cleaved by proteases including calpain and caspase-3 in a calcium-dependent manner to produce SBDPs. In the central nervous system, this modulation plays an important physiological role in neuroplasticity under normal conditions. However, this signal pathway is persistently activated under cellular stress, during aging and in a variety of neurodegenerative diseases. Currently, SBDPs are being evaluated as novel biomarkers for traumatic and ischemic brain injury. It is worthy exploring whether these biomarkers may be also useful for detection/assessment of neuronal injury in the brain in chronic neurodegenerative diseases such as Alzheimer’s disease. This idea can be approached by carrying out additional basic and translational studies using existing animal models for human neurodegenerative diseases.